Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (October 2022)
16 slides from Genetic Signatures's investor presentation, October 2022
Slide 1: Investor Presentation October 2022
Investor Presentation October 2022
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer October 2022 2021 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation concerning the
Slide 3: Investment highlights
Investment highlights Investor DOCUMENT Presentation TITLE October 2022 2021 Proprietary 3base® technology platform that provides a revolutionary approach for molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiplexing) • More informative – detect relat
Slide 4: Recent Events
Recent Events Investor DOCUMENT Presentation TITLE October 2022 2021 US FDA clinical trial recruitment completed • Targeting 4Q CY2022 application for clearance 3base® kit for antimicrobial resistance shows high detection rate • Independent study1 showed excellent biological performance for the 5 mo
Slide 5: Company Snapshot
Investor DOCUMENT Presentation TITLE Company Snapshot October 2022 2021 Financial information Share price Volume (m) (A$) Share price (11-Oct-22) A$0.85 2.00 4.00 1.80 Shares on issue 143.4m 3.50 1.60 3.00 Market capitalisation A$121.9m 1.40 2.50 Cash (30-Jun-22) A$36.9m 1.20 1.00 2.00 Debt (30-Jun-
Slide 6: Track record of continued, strong revenue growth
Investor DOCUMENT Presentation TITLE Track record of continued, strong revenue growth October 2022 2021 Sales Revenue (A$m) FY22 sales revenue of $35.4 million (+25% yoy, 89% 4yr CAGR) Growing contribution from international sales Other 35.4 • Leveraging experience in Australian market; 11% 4.9 • Eu
Slide 7: 3base® - a revolution in molecular diagnostics
3base® - a revolution in molecular diagnostics Investor DOCUMENT Presentation TITLE October 2022 2021 Molecular diagnostic tests are based on DNA/RNA sequences • DNA/RNA is unique to each organism. Molecular diagnostic tests are recognised as the ‘gold standard’ • Precisely targeted and highly speci
Slide 8: How 3base® simplifies molecular targets
Investor DOCUMENT Presentation TITLE How 3base® simplifies molecular targets October 2022 2021 G A T G G C G A C A Genetic Signatures 3base® technology converts all C T G A T G G T G A T A G A T G G T G A T A Molecular target becomes the same for G A T G G T G A C A all three test sequences * Human
Slide 9: How 3base® tests are performed
Investor DOCUMENT Presentation TITLE How 3base® tests are performed October 2022 2021 Proprietary method - patented until 2031+ Benefits 1. Extraction and Conversion • natural 4 bases to 3base® Rapid High throughput Informative Sensitive Specific Low manual involvement 2. DNA Amplification (PCR) Red
Slide 10: 3base® simplifies Syndromic Testing – EasyScreen™ Kits
3base® simplifies Syndromic Testing – EasyScreen™ Kits Investor DOCUMENT Presentation TITLE October 2022 2021 Syndromic testing: simultaneously test for multiple pathogens that all can cause the same signs and symptoms • Respiratory infections: cough, runny nose, sore throat, headache, breathlessnes
Slide 11: Robust pipeline with multiple products cleared for sale
Investor DOCUMENT Presentation TITLE Robust pipeline with multiple products cleared for sale October 2022 2021 DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 11
Slide 12: Growth initiatives
Investor DOCUMENT Presentation TITLE Growth initiatives October 2022 2021 Leverage experience in Australian market to grow international sales • Europe – drive adoption of other 3base® products; • US – build 3base® franchise once Protozoan Detection Kit is cleared. Build and expand portfolio of comm
Slide 13: Enteric Protozoan kit will provide entry to North America
Investor DOCUMENT Presentation TITLE Enteric Protozoan kit will provide entry to North America October 2022 2021 Enteric Protozoan Screening Kit • Completed recruitment for 1,500 subject clinical trial; • Targeting 510(k) submission in Q4 CY2022; • First EasyScreen™ product for US High need for Ente
Slide 14: New products and instruments
Investor DOCUMENT Presentation TITLE New products and instruments October 2022 2021 Expand available EasyScreen™ Syndromic Kits • 3 kits research use only (RUO) – tropical diseases, MMR & meningitis; • Other kits in development (tick-borne, skin infections, etc.); • Advance additional 3 products thr
Slide 15: Upcoming milestones – 12 months
Upcoming milestones – 12 months Investor DOCUMENT Presentation TITLE October 2022 2021 US Enteric Protozoan Kit • File 510(k) application by end of CY2022; • Launch product once clearance is granted. Increase sales and presence in UK and European markets • Contracts with new customers; • Direct sale
Slide 16: Contact Us
Contact Us Dr John Melki Genetic Signatures Ltd Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us www.geneticsignatures.com Follow us 16
Genetic Signatures — Investor Presentation (October 2022) on 6ix